(Q35982992)

11 August 2017

The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected] (English)

1 reference

11 August 2017

Stein RC

1

1 reference

11 August 2017

Malkovska V

2

1 reference

11 August 2017

Morgan S

3

1 reference

11 August 2017

Galazka A

4

1 reference

11 August 2017

Aniszewski C

5

1 reference

11 August 2017

Roy SE

6

1 reference

11 August 2017

Shearer RJ

7

1 reference

11 August 2017

Marsden RA

8

1 reference

11 August 2017

Bevan D

9

1 reference

11 August 2017

Gordon-Smith EC

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 1991

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

63

1 reference

11 August 2017

2

1 reference

11 August 2017

275-278

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1991.64

11 August 2017

0 references

cites work

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

T cell growth factor: parameters of production and a quantitative microassay for activity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

The international standard for human interleukin-2. Calibration by international collaborative study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Characterization of human interleukin 2 derived from Escherichia coli

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1971786

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

24 September 2018

1 reference

12 December 2020

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

12 December 2020

Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1991.64

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

1 reference